Home › Sindromi mielodisplastiche › Texas
Studi clinici su Sindromi mielodisplastiche nello stato di Texas
44 studi su Sindromi mielodisplastiche cercano partecipanti presso sedi nello stato di Texas.
Città nello stato di Texas
Testo ufficiale dello studio (inglese)
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- University of Texas MD Anderson Cancer Center, Houston
In reclutamentoFase 1
Età da 12 a 78 · Tutti i sessi · Aggiornato il 29 set 2026 · NCT03802695MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05564390A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
- MD Anderson Cancer Center, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06548230Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 set 2026 · NCT03661307Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- MD Anderson, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT05320198A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- World Research Link, Baytown
- Texas Oncology - Denton, Denton
- The Center for Cancer and Blood Disorders, Fort Worth
- e altri 3
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 set 2026 · NCT07422480Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- M D Anderson Cancer Center, Houston
In reclutamentoFase 1
Età 1 e oltre · Tutti i sessi · Aggiornato il 18 set 2026 · NCT03630991Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- M D Anderson Cancer Center, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT03471260Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
- M D Anderson Cancer Center, Houston
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT03683433A Study of BGB-11417 in Participants With Myeloid Malignancies
- Md Anderson Cancer Center, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT04771130A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
- MD Anderson Cancer Center, Houston
In reclutamentoFase 2Volontari sani benvenuti
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 set 2026 · NCT06566742A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
- The University of Texas MD Anderson Cancer Center, Houston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 set 2026 · NCT06616636ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT05010122Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- University of Texas UT Southwestern Comprehensive Cancer Center, Dallas
- MD Anderson Cancer Centre, Houston
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT06465953CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT04493164The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- e altri 10
In reclutamentoFase 1/2
Fino a 22 anni · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Texas Oncology Northeast Texas, Denison
- U.T. MD Anderson Cancer Center, Division of Cancer Medicine, Houston
- Texas Oncology Gulf Coast, The Woodlands
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 ago 2026 · NCT06499285A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
- Univ of Texas MD Anderson Cancer Center, Division of Cancer Medicine, Houston
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 ago 2026 · NCT04419649Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- M D Anderson Cancer Center, Houston
In reclutamentoFase 2/3Volontari sani benvenuti
Età da 18 a 70 · Tutti i sessi · Aggiornato il 11 ago 2026 · NCT04708054Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
- University of Texas, Southwestern, Dallas
- MD Anderson Cancer Center, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 ago 2026 · NCT05308264Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
- M D Anderson Cancer Center, Houston
In reclutamentoFase 1/2
Età da 12 a 80 · Tutti i sessi · Aggiornato il 7 ago 2026 · NCT05092451Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
In reclutamentoFase 2
Età da 15 a 80 · Tutti i sessi · Aggiornato il 30 lug 2026 · NCT02727803Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Research Site, Houston
In reclutamentoFase 1/2
Età 16 e oltre · Tutti i sessi · Aggiornato il 20 lug 2026 · NCT07155226Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
- University of Texas MD Anderson Cancer Center, Houston
In reclutamentoFase 2
Età 60 e oltre · Tutti i sessi · Aggiornato il 16 lug 2026 · NCT01515527Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 giu 2026 · NCT01624805SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- MD Anderson Cancer Center, Houston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 giu 2026 · NCT03113643Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
- UT Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 giu 2026 · NCT02074839A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
- M D Anderson Cancer Center, Houston
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 giu 2026 · NCT05365035A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
- GSK Investigational Site, Houston
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 giu 2026 · NCT06847867Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
- MD Anderson, Houston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 mag 2026 · NCT04953897Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
- MD Anderson, Houston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 mag 2026 · NCT04953910A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
- M D Anderson Cancer Center, Houston
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 20 mag 2026 · NCT04239157Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- M D Anderson Cancer Center, Houston
In reclutamentoFase 2
Età da 18 a 65 · Tutti i sessi · Aggiornato il 20 mag 2026 · NCT02115295A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 apr 2026 · NCT04256317A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- The University of Texas MD Anderson Cancer Center, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 apr 2026 · NCT05732103Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
- MD Anderson Cancer Center, Houston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 mar 2026 · NCT07107126A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- MDACC, Houston
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 24 mar 2026 · NCT04988555Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
- Mays Cancer Center at UT Health San Antonio, San Antonio
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 20 feb 2026 · NCT05745285CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- MD Anderson, Houston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 gen 2026 · NCT05143996Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
- M.D. Anderson Cancer Center, Department of Leukemia, Houston
In reclutamentoFase 1Volontari sani benvenuti
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 nov 2025 · NCT05986240Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.